Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Completed
Shire
Phase 3
2005-04-08
Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of
the bowel becomes red and swollen. Over time, patients with this disease may experience acute
episodes of diarrhea, rectal bleeding and abdominal pain followed by periods of time without
disease symptoms. 5-ASA drugs are a standard treatment for ulcerative colitis. Mesalazine is
an experimental drug designed to gradually release 5-ASA into the areas of large bowel
associated with ulcerative colitis. This study will test the safety and efficacy of
mesalazine in keeping ulcerative colitis in remission.
Strategies in Maintenance for Patients Receiving Long-term Therapy (S.I.M.P.L.E.) With MMX (Multi-Matrix System) Mesalamine for Ulcerative Colitis (UC)
Completed
Shire
Phase 4
2007-05-01
To evaluate the percentage of subjects with clinical recurrence of UC at 6 months using MMX
mesalamine once daily.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 4
2008-09-01
The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin
(FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of
relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels
The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin
(FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of
relapse among patients with quiescent ulcerative colitis. Sixty patients with FCP levels
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
